Assessment of clinical usefulness of 131I-alpha-methyl-tyrosine and fused SPECT/MRI imaging for diagnostics of recurrent cerebral gliomas

Nuclear Medicine Review

Volumn 7, Issue 2, 2004, Pages 135-141

  Górska Chrzastek, Magdalena ^a   Grzelak, Piotr ^a   Bieńkiewicz, Małgorzata ^a   Gasiński, Piotr ^a   Tybor, Krzysztof ^a   Zakrzewska, Edyta ^b   Mikołajczak, Renata ^b   Stefańczyk, Ludomir ^a   Kuśmierek, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

Author keywords

131I alpha methyl tyrosine; Glioma; MRI SPECT image fusion

Indexed keywords

IODINE 123; IODINE 131; METIROSINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG SUBSTITUTION; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTAXIC SURGERY;

ADULT; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLTYROSINES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 12344264841     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Jaskólski DJ, Papierz W, Rieske P, Biernat W, Liberski P. Tumours of the central nervous system In the light of the WHO 2000 classification. Aktualności Neurologiczne 2001; 2: 200-235.
2. Waker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985; 35: 219-226.
3. Annegers JF, Schoenberg BS, Okazaki H, Kurland LT. Epidemiologic study of primary intracranial neoplasms. Arch Neurolol 1981; 38: 217-219.
4. Loeffler JS, Alexander E III, Wen PY. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst 1990; 82: 1918-1921.
5. Shenouda G, Souhami L, Podgorsak EB. Radiosurgery and accelerated radiotherapy for patients with glioblastoma. Can J Neurol Sci 1997; 24: 110-115.
6. Lacroix M, Abi-Said D, Fourney DR. A multivariate analysis of 416 patients with glioblasoma multiforme: prognosis, extent of resection and survival. J Neurosurgery 2001; 95: 190-198.
7. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurgery 2001; 95: 735-745.
8. Fine HA, Dear KB, Loeffler JS. Meta-analysis of radiation therapy with and without adjuvant chemiotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-2597.
9. Harsh GR IV, Levin VA, Gutin PH. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 1987; 21: 615-621.
10. Ryterski J, Pytlewski A, Bogusławska R, Skrzyński S, Twarkowski P. MR imaging of postoperative changes in the brain. Rez Magn Med 1998; 6: 17-22.
11. Elster A, DiPersio D. Cranial postoperative site: assessment with contrast-enhanced MR imaging. Radiology 1990; 174: 93-98.
12. Henegar M, Moran C, Silbergeld D. Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 1996; 84: 174-179.
13. Jeffries B, Kishore P, Singh et al. Contrast Enhancement in the post-operative brain. Radiology 1981; 139: 409-413.
14. Sato N, Bronen R, Sze G et al. Postoperative changes in the brain: MR imaging findings in patients without neoplasms. Radiology 1997; 204: 939-846.
15. Spetzger U, Thorn A, Glisbach J. Immediate postoperative CT contrast enhancement following susgery of cerebral tumoral lesions. J Com Assist Tomogr 1998; 22: 120-125.
16. Bruhn H, Frahm J, Gyngell M et al. Noninvasive differentiation of tumors with use of localized H1MR spectroscopy in vivo: Initial experience in patients with cerebral tumors. Radiology 1989; 172: 541-548.
17. Fulham MJ, Bizzi A, Dietz MJ et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992; 185: 675-686.
18. Mateja P, Schober O. 123I-IMT SPET: introducing another research tool into clinical neuro-oncology? Eur J Nucl Med 2001; 28: 1-4.
19. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumours; a powerful diagnostic and prognostic tool. Invest Radiol 1986; 22: 360-371.
20. Langen KJ, Pauleit D, Coenen H. 3-(123I)iodo-alfa-methyl-L-tyrosine: uptake mechanism and clinical applications. Nucl Med and Biol 2002; 29: 625-631.
21. Stokking R, Zuiderveld KJ, Holleke E et al. Normal fusion for three-dimensional integrated visualization of SPECT and Magnetic Resonance brain images. J Nucl Med 1997; 38: 624-629.
22. Nariari T, Senda M, Ishii K et al. Three-dimensional imaging of cortical structure function and glioma for tumor resection. J Nucl Med 1997; 38: 1563-1568.
23. Stokking R, van Isselt JW, van Rijk PP et al. Integrated visualisation of functional and anatomic brain data; a validation study. J Nuclear Med 1999; 40: 311-316.
24. Zuchora Z, Makarewicz R. Fuzje obrazów - zastosowanie w onkologii - teraźniejszość i perspektywy. Probl Med Nukl 2002; 16: 25.
25. Gajewicz W, Grzelak P, Rotkiewicz A et al. Przydatność obrazów fuzyjnych RM i SPECT do planowania protonowej spektroskopii RM (1HMRS) w diagnostyce nowotworów mózgu - doniesienie wstepne. Twój Magazyn Medyczny Ultrasonografia i Radiologia 2004; 447-453.
26. Biersack H-J, Coenen HH, Stocklin G et al. Imaging of brain tumors with L-3-(123I)iod-methyl tyrosine and SPECT. J Nucl Med 1989; 30: 110-112.
27. 123I]iodo-L-alpha-methyltyrosine transport in rat C6 glioma cells. Eur J Nucl Med 1999; 26: 1274-1278.
28. Weckesser M, Griesmeier M, Schmidt D et al. Iodine-123 alfa-methyl tyrosine single-photonemission tomography of cerebral gliomas: standardized evaluation of tumour uptake and extent. Eur J of Nucl Med 1998; 25: 150-156.
29. Kuwert T, Woesler B, Morgenroth C et al. Diagnosis of recurrent glioma with SPECT and iodine-123-alfa-methyl tyrosine. J Nucl Med 1998; 39: 23-27.
30. Kuwert T, Probst-Cousin S, Woesler B et al. Iodine-123-alfa-methyl tyrosine in gliomas: correlation with cellular denstity and proliferative activity. J Nucl Med 1997; 38: 1551-1555.
31. Saier MH Jr, Daniels GA, Boerner P, Lin J. Neutral amino acids transport system in animal cells; potential targets of oncogene action and regulators of cellular growth. J Membr Biol 1988; 104: 1-20.
32. Kuwert T, Morgenroth C, Woesler B et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996; 23: 1345-1353.
33. Riemann B, Papke K, Kuwert T et al. Noninvasive grading of untreated gliomas; a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT. Radiology 2002; 225: 567-574.
34. Schmidt D, LangenK-J, Herzog H et al. Whole-body kinetics and dosimetry of L-3(123I)iodo-alfa-methyltyrosine. Eur J Nucl Med 1997; 24: 1162-1166.
35. Radiation Dose to Patients from Radiopharmaceuticals ICRP Publ. No 53; Annals of the ICRP: Vol. 18, No. 1-4, 1987.
36. Radiation Dose to Patients from Radiopharmaceuticals (Addendum to ICRP 53 and 72) ICRP Publ. No 80; Annals of the ICRP; Vol. 28, No. 3, 1998.